Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCT-021 in Healthy Adults for SARS-CoV-2
NCT04480957Phase 2Completed
- Sponsor
- Arcturus Therapeutics
- Start
- Aug 2020
- Primary completion
- Jan 2021
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ARCT-021 in coronavirus disease 2019 (COVID-19), sponsored by Arcturus Therapeutics. Started Aug 2020; status: completed.
02
Drugs
ARCT-021
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04480957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04480957.